Why Is PDL BioPharma (PDLI) Up 4.6% Since Last Earnings Report?

- Advertisement -
- Advertisement -
- Advertisement -
- Advertisement -

It has been about a month since the last earnings report for PDL BioPharma (PDLI). Shares have added about 4.6% in that time frame, underperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is PDL BioPharma due for a pullback? Before we dive into how investors and analysts have reacted as of late, let’s take a quick look at its most recent earnings report in order to get a better handle on the important drivers.

 

 

It has been about a month since the last earnings report for PDL BioPharma (PDLI). Shares have added about 4.6% in that time frame, underperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is PDL BioPharma due for a pullback? Before we dive into how investors and analysts have reacted as of late, let’s take a quick look at its most recent earnings report in order to get a better handle on the important drivers.

PDL BioPharmaMisses on Q4 Earnings, To Dissolve by Year-End

PDL BioPharma reported earnings of 3 cents per share (including the impact of stock-based compensation expense) in the fourth quarter of 2019, missing the Zacks Consensus Estimate of 5 cents. The bottom line was also lower than the year-ago earnings of 10 cents.

The company reported total revenues of a negative $5.8 million in the quarter against the positive $46 million generated in the prior year. The negative revenues were due to a change in the fair value of royalty rights.

PDL announced a plan to dissolve the company by the end of 2020.

It has been about a month since the last earnings report for PDL BioPharma (PDLI). Shares have added about 4.6% in that time frame, underperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is PDL BioPharma due for a pullback? Before we dive into how investors and analysts have reacted as of late, let’s take a quick look at its most recent earnings report in order to get a better handle on the important drivers.

PDL BioPharmaMisses on Q4 Earnings, To Dissolve by Year-End

PDL BioPharma reported earnings of 3 cents per share (including the impact of stock-based compensation expense) in the fourth quarter of 2019, missing the Zacks Consensus Estimate of 5 cents. The bottom line was also lower than the year-ago earnings of 10 cents.

The company reported total revenues of a negative $5.8 million in the quarter against the positive $46 million generated in the prior year. The negative revenues were due to a change in the fair value of royalty rights.

PDL announced a plan to dissolve the company by the end of 2020.

Home of Science
Follow me

- Advertisement -

Discover

Sponsor

Latest

Elon Musk holds Twitter vote over $21bn Tesla share saleon November 7, 2021 at 11:52 am

The Tesla boss promises to honour the outcome of the poll, whichever way it goes.

The Papers: Russia-Ukraine tensions and No 10 police quizzedon January 24, 2022 at 12:13 am

The papers report on the partygate investigation and fears that gas prices might rise if Russia invades Ukraine.

Food bills are set to soar by £380 this yearon June 21, 2022 at 9:37 am

As grocery prices rise at their highest pace in 13 years, experts warn there are more hikes to come.Image source, Getty ImagesThe average grocery...

Sara Bjork Gunnarsdottir wins landmark football maternity pay rulingon January 18, 2023 at 6:46 am

Former Lyon midfielder Sara Bjork Gunnarsdottir says the £72,000 of back-dated maternity pay awarded to her is a "wake-up call" for clubs.Former Lyon midfielder...

UK economy boosted by holidays and dining outon October 13, 2021 at 8:44 am

GDP rose 0.4% in August in the first full month after all Covid restrictions were lifted in England.Image source, Getty ImagesThe UK economy grew...
Home of Science
Follow me